Taevas
SingaporePharmaceuticals
Legal Representation
Legal Representation for Pharmaceuticals in Singapore
Taevas Global provides dedicated local legal representation to help pharmaceuticals manufacturers meet Health Sciences Authority requirements and establish a compliant, commercially ready presence in Singapore. From product registration to ongoing regulat
Market
Singapore
Industry
Pharmaceuticals
Service
Legal Representation
Regulator
Health Sciences Authority (HSA)
Timeline
4-6 weeks onboarding
What We Deliver
Six Pillars of Singapore Pharmaceuticals Intelligence
Our legal representation service is built on six interconnected pillars that together cover every regulatory, commercial, and compliance dimension a pharmaceuticals company needs to operate confidently in Singapore.
01
HSA Regulatory Compliance
We act as your appointed local legal representative under the Health Products Act, ensuring your products and operations satisfy all Health Sciences Authority requirements. Our team monitors regulatory updates from HSA and translates them into actionable compliance steps for your product portfolio. This pillar forms the foundation of a sustainable Singapore market presence.
Appointed local legal representative under Health Products Act
Ongoing HSA regulatory monitoring and alert service
Compliance gap assessments against current HSA guidelines
How It Works
From Brief to Board-Ready Intelligence
Our four-stage engagement model takes you from initial scoping through to a fully operational legal representation structure in Singapore, with clear milestones and dedicated account management at every step.
Step 1 · Day 1-2
Regulatory Scoping and Needs Assessment
We begin with a structured intake session to understand your product portfolio, current registration status, target launch timeline, and distribution model in Singapore. Our regulatory team reviews your existing dossiers and identifies gaps against HSA requirements for each product. This assessment produces a prioritised action plan and engagement scope.
Taevas Approach
The scoping session covers therapeutic product classification, applicable HSA evaluation routes, import and dealer licensing requirements, pharmacovigilance obligations, and any unique considerations such as controlled drug scheduling or biosimilar pathways. Deliverable: a written regulatory gap report and proposed engagement scope with timeline and fee estimate.
Market Snapshot
Singapore Pharmaceuticals Market at a Glance
S$0B+
Pharmaceuticals Manufacturing Output (2023)
0%
Projected Annual Market Growth Rate
0+
Global Pharma MNCs with Singapore Operations
0+
Registered Therapeutic Products on HSA Register
Asia-Pacific Manufacturing Hub
Singapore is one of the world's top five pharmaceutical export nations by value, with global majors including Pfizer, Novartis, and GSK operating large-scale manufacturing facilities on the island. The Economic Development Board actively incentivises pharmaceutical investment through Pioneer Status and Development and Expansion Incentive schemes. This makes Singapore a strategic base for regional and global supply chain operations.
Rigorous HSA Regulatory Framework
The Health Sciences Authority administers one of Asia's most respected pharmaceutical regulatory systems, with its product approvals widely recognised by ASEAN member states and used as reference approvals in multiple markets. HSA's regulatory framework is aligned with ICH guidelines and the ASEAN Common Technical Dossier, reducing duplication for companies with existing EU or US approvals. Compliance with HSA standards is therefore both a market entry requirement and a regional credentialing asset.
Strong Regional Gateway Position
Singapore's membership in the ASEAN Pharmaceutical Product Working Group and its adoption of ASEAN harmonised guidelines means a Singapore registration can accelerate market access across a 680-million-person regional market. The country's free trade agreements with major pharmaceutical exporting nations further reduce tariff and non-tariff barriers for registered products. Companies that establish regulatory standing in Singapore gain a meaningful first-mover advantage across Southeast Asia.
Growing Biologics and Biosimilars Sector
Singapore has invested heavily in biomedical sciences infrastructure, with Biopolis housing over 50 biomedical research and manufacturing organisations. HSA published its Guidance on Registration of Biosimilar Products and has approved a growing number of biosimilar products, reflecting increasing market sophistication. Pharmaceutical companies entering the biologics and biosimilars space will find Singapore's regulatory environment well-prepared and commercially receptive.
What's Included
Everything in Your Engagement
Every Taevas Global Legal Representation engagement for Pharmaceuticals in Singapore includes these eight core deliverables, structured to give your leadership team full visibility and your regulatory team operational confidence.
Regulatory Gap Assessment Report
A written analysis of your current product and licensing status against HSA requirements, with a prioritised remediation roadmap and estimated timelines for each action item.
HSA Appointment Documentation
Fully prepared and executed local legal representative appointment documents, filed with HSA and maintained for the duration of the engagement.
Product Registration Dossiers
Complete CTD-format dossiers prepared, quality-checked, and submitted via the HSA PRISM portal for each product in scope, with query management included.
Import and Dealer Licence Applications
End-to-end management of all required Health Products Act licence applications, including preparation of supporting documentation and liaison with HSA's Audit and Licensing Division.
Compliance Calendar and Tracker
A live digital compliance calendar covering all HSA submission deadlines, licence renewal dates, pharmacovigilance reporting windows, and regulatory review milestones for your Singapore portfolio.
Pharmacovigilance System Setup
Establishment of a Singapore-compliant pharmacovigilance system including adverse event intake procedures, HSA reporting workflows, and PSUR preparation protocols.
Labelling and Advertising Review
Pre-market review of all product labels, package inserts, and promotional materials against current HSA requirements, with written clearance confirmation and variation submission management.
Quarterly Compliance Review Meetings
Structured quarterly reviews with your dedicated Taevas account manager covering regulatory developments, portfolio status, upcoming deadlines, and strategic market access opportunities.
Who This Is For
Built for These Situations
Market Entry
Overseas Manufacturer Entering Singapore for the First Time
Your company has regulatory approval in your home market and is ready to expand into Singapore and ASEAN, but you lack a local entity or regulatory team on the ground. HSA requires a locally appointed legal representative before any therapeutic product can be registered or sold in Singapore. Taevas Global provides that local presence immediately, without the cost and delay of establishing your own Singapore subsidiary.
Outcome
Achieve HSA product registration and full market-ready status within your target launch window, with all local compliance obligations covered from day one.
Next Steps
After Legal Representation, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Establish Your Singapore Presence?
Speak with a Taevas Global regulatory specialist today to assess your HSA requirements, map your product registration pathway, and get a transparent proposal for legal representation services tailored to your pharmaceuticals portfolio.
HSA-compliant local legal representative appointed within weeks
Full product registration and licensing management included
Dedicated account manager with Singapore pharmaceutical expertise
ASEAN market access strategy integrated from day one